Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

被引:89
|
作者
Prado, JG
Wrin, T
Beauchaine, J
Ruiz, L
Petropoulos, CJ
Frost, SDW
Clotet, B
D'Aquila, RT
Martinez-Picado, J
机构
[1] Univ Autonoma Barcelona, Hosp Germans Trias Pujol, IrsiCaixa Fdn, Barcelona 08916, Spain
[2] Virolog Inc, San Francisco, CA USA
[3] Univ Calif San Diego, Dept Pathol, San Diego, CA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
amprenavir; HIV-1 drug resistance; lopinavir; protease inhibitors; replication capacity; viral fitness;
D O I
10.1097/00002030-200205030-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate protease inhibitor (PI) cross-resistance and reductions in replication capacity conferred by amprenavir-selective mutations. Methods: HIV-1(IIIB) variants derived from passage in increasing concentrations of amprenavir were studied, as well as 3'Gag/protease recombinants derived from them. These strains progressively accumulated mutations at codons 10, 46, 47, 50 and 84 in the protease as well as a p1/p6 cleavage site mutation at codon 449 in Gag. Their susceptibility (IC50) to various PI and their corresponding replication capacities were evaluated by a single-cycle growth assay and compared with measures using competitive cultures and p24 antigen production. Results: Amprenavir susceptibility decreased with increasing numbers of protease mutations. Changes in lopinavir susceptibility paralleled changes in amprenavir susceptibility. Certain amprenavir-selected mutants conferred greater than 10-fold cross-resistance to lopinavir, including PrL10F/M461/150V-GagL449F (19-fold) and PrL10F/M46I/147V/150V-GagL449F (31-fold). Moreover, one isolate with only two mutations in the protease (L10F/84V) and GagL449F displayed a 7.7-fold increase in lopinavir IC50. Low-level cross-resistance to ritonavir and nelfinavir was also observed. The replication capacity of viruses containing either 184V or 150V was at least 90% lower than the reference virus in the single-cycle assay. The order of relative replication capacity was wild-type > L10F > L10F/184V > L10F/M461/150V > L10F/M461/147V/150V. Conclusion: These results indicate that until more comprehensive genotype-phenotype correlations between amprenavir and lopinavir susceptibility are established, phenotypic testing may be preferable to genotyping to detect cross-resistance, and should be considered when switching patients from a failing amprenavir-containing regimen. This study also provides data on the concordance of replication capacity measurements generated using rapid single-cycle growth and competition assays. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:1009 / 1017
页数:9
相关论文
共 50 条
  • [1] Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors
    Aoki, Manabu
    Venzon, David J.
    Koh, Yasuhiro
    Aoki-Ogata, Hiromi
    Miyakawa, Toshikazu
    Yoshimura, Kazuhisa
    Maeda, Kenji
    Mitsuya, Hiroaki
    [J]. JOURNAL OF VIROLOGY, 2009, 83 (07) : 3059 - 3068
  • [2] Mutations in HIV-1 protease associated with resistance to amprenavir contribute towards phenotypic resistance to lopinavir
    Parkin, NT
    Chappey, C
    Petropoulos, CJ
    [J]. ANTIVIRAL THERAPY, 2002, 7 : S29 - S29
  • [3] Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia
    Paulsen, D
    Liao, QM
    Fusco, G
    St Clair, M
    Shaefer, M
    Ross, L
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (14) : 1011 - 1019
  • [4] Evaluation of replication capacity and cross-resistance of HBV drug resistant mutants
    Villet, S.
    Lucifora, J.
    Brunelle, M. N.
    Trepo, C.
    Durantel, D.
    Zoulim, F.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S23 - S23
  • [5] Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance
    Parkin, NT
    Chappey, C
    Petropoulos, CJ
    [J]. AIDS, 2003, 17 (07) : 955 - 961
  • [6] Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples
    Schnell, T
    Schmidt, B
    Moschik, G
    Thein, C
    Paatz, C
    Korn, K
    Walter, H
    [J]. AIDS, 2003, 17 (08) : 1258 - 1261
  • [7] HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
    Rhee, Soo-Yon
    Taylor, Jonathan
    Fessel, W. Jeffrey
    Kaufman, David
    Towner, William
    Troia, Paolo
    Ruane, Peter
    Hellinger, James
    Shirvani, Vivian
    Zolopa, Andrew
    Shafer, Robert W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4253 - 4261
  • [8] Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model
    Marieke Pingen
    Ramin Sarrami-Forooshani
    Annemarie MJ Wensing
    Petra van Ham
    Agata Drewniak
    Charles AB Boucher
    Teunis BH Geijtenbeek
    Monique Nijhuis
    [J]. Retrovirology, 11
  • [9] Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model
    Pingen, Marieke
    Sarrami-Forooshani, Ramin
    Wensing, Annemarie M. J.
    van Ham, Petra
    Drewniak, Agata
    Boucher, Charles A. B.
    Geijtenbeek, Teunis B. H.
    Nijhuis, Monique
    [J]. RETROVIROLOGY, 2014, 11
  • [10] Replication capacity and drug susceptibility of lopinavir-resistant HIV-2
    Mo, H.
    Lu, X.
    Masse, S.
    Dekhtyar, T.
    Lu, L.
    Mondal, R.
    Koev, G.
    Ng, T.
    Bernstein, B.
    Gao, F.
    Molla, A.
    [J]. ANTIVIRAL THERAPY, 2006, 11 (05) : S49 - S49